2,2,2-Trifluoroethyl trifluoromethanesulfonate → 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)piperidin-4-ylmethoxy]quinazoline

HRID 916425노트

반응식

HRID 916425 반응식
[F:1][C:2]1[C:10]([O:11][C:12]2[C:21]3[C:16](=[CH:17][C:18]([O:24][CH2:25][CH:26]4[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]4)=[C:19]([O:22][CH3:23])[CH:20]=3)[N:15]=[CH:14][N:13]=2)=[CH:9][CH:8]=[C:7]2[C:3]=1[CH:4]=[C:5]([CH3:32])[NH:6]2.C(N(C(C)C)CC)(C)C.FC(F)(F)S(O[CH2:48][C:49]([F:52])([F:51])[F:50])(=O)=O>O1CCCC1>[F:1][C:2]1[C:10]([O:11][C:12]2[C:21]3[C:16](=[CH:17][C:18]([O:24][CH2:25][CH:26]4[CH2:31][CH2:30][N:29]([CH2:48][C:49]([F:52])([F:51])[F:50])[CH2:28][CH2:27]4)=[C:19]([O:22][CH3:23])[CH:20]=3)[N:15]=[CH:14][N:13]=2)=[CH:9][CH:8]=[C:7]2[C:3]=1[CH:4]=[C:5]([CH3:32])[NH:6]2

참가 물질

5

반응물 3

HCID 803662,2,2-Trifluoroethyl trifluoromethanesulfonate2회HCID 81531Diisopropylethylamine2회HCID 589602204-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline

생성물 1

HCID 102893704-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)piperidin-4-ylmethoxy]quinazoline수율 44%

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

실험 절차

4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline (180 mg, 0.41 mmol), (prepared as described for the starting material in Example 11), was suspended in tetrahydrofuran (15 ml), and diisopropylethylamine (108 μl, 0.45 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulphonate (98 mg, 0.62 mmol) were added. The mixture was heated at reflux for 1.5 hours. Diisopropylethylamine (36 μl, 0.21 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulphonate (45 mg, 0.21 mmol) were added and the mixture was heated at reflux for a further 2 hours. The mixture was concentrated under reduced pressure and column chromatography of the residue, eluting with 1% methanol/methylene chloride gave a sticky solid. This was triturated with diethyl ether and filtered to give 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)piperidin-4-ylmethoxy]quinazoline (93 mg, 44%).

후처리

  1. temperatureThe mixture was heated
  2. temperatureat reflux for 1.5 hours
  3. temperaturethe mixture was heated
  4. temperatureat reflux for a further 2 hours
  5. concentrationThe mixture was concentrated under reduced pressure and column chromatography of the residue
  6. washeluting with 1% methanol/methylene chloride
  7. customgave a sticky solid
  8. customThis was triturated with diethyl ether
  9. filtrationfiltered

출처 및 근거

ORD 기록
ord-0994bc4136dd483582a7f04a5b3710c9
출처 데이터셋
uspto-grants-2007_09
특허 번호
US07268230B2

반응 노트

불러오는 중…